{"description":"All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed.","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":0,"description":"Patients with non-squamous NSCLC regardless of genomic alteration status (newly diagnosed or progressing on therapy)","id":"EG000","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"title":"A - NSCLC All Comers Regardless of Genomic Alteration Status"},{"deathsNumAffected":0,"deathsNumAtRisk":0,"description":"Patients with non-squamous NSCLC progressing on erlotinib, gefitinib, or afatinib","id":"EG001","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"title":"B - Progressing on EGFR Targeted Therapies"}],"frequencyThreshold":"0"}